433P - Efficacy and safety of bevacizumab (BV) and irinotecan (I) in elderly patients with recurrent glioblastoma multiform (GBM): A monocentric retrospec...

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Geriatric Oncology
Central Nervous System Malignancies
Presenter Marie Robert
Citation Annals of Oncology (2014) 25 (suppl_4): iv137-iv145. 10.1093/annonc/mdu330
Authors M. Robert1, C. Leux2, C. Gourmelon1, M. Campone3, J. Frenel1
  • 1Centre René Gauducheau, Institut de Cancérologie de l'Ouest, FR-44805 - St Herblain CEDEX/FR
  • 2Phu Santé Publique Et Santé Au Travail, Centre Hospitalier Universitaire de Nantes, 44093 - Nantes/FR
  • 3Medical Oncology, Institut de Cancérologie de l’Ouest - René Gauducheau, Herblain/FR



The combination of BV + I is an option for the treatment of recurrent GBM. However, its use in elderly patients remains controversial.


We retrospectively reviewed the medical records of all the patients who received BV + I for recurrent GBM in our institution. GBM histology/grade IV astrocytoma progressing after concurrent radiotherapy with temozolomide were retrieved. Toxicity, overall survival (OS) and progression free survival (PFS) were compared between patients < 65 and ≥ 65 years old.


From 2007 to 2013, 84 patients were included (Male 52/Female32), reparted in < 65 years old (group A), n= 54 and ≥ 65 years old (group B), n = 30. Performans status at relapse was 0-1 (n = 50) or >2 (n = 23). The most frequent grade 3-4 adverse events were veinous thromboembolic events (6 in the group A vs 1 in the group B) and asthenia (3 vs 2). Hypertension and asthenia were more reported in elderly patients: 20% vs 3,7% (HR 6,5; 95%CI : 1,22-34,59, p = 0,028) and 76,7% vs 48,1% (HR 3,54; 95%CI : 1,3-9,62; p = 0,013) respectively. Patient >65y had a similar PFS and OS with B + I than those <65y: median PFS were respectively 7.1 months (95%CI, 6.0-8.8) versus 6.2 months (95%CI, 5.4-7.5) and median OS 8.5 months (95%CI, 7.1-13.5) versus 8.9 months (95%CI, 7.3-11.0).


In this study, BV + I in >65y patients is as effective and safe as in <65y patients.


All authors have declared no conflicts of interest.